• Announcement

The SMA website will undergo scheduled maintenance on Friday, 24 April, from 10:00 PM to Saturday, 25 April, 4:00 AM and will be unavailable during this time.

Thank you for your patience. For enquiries, please contact sma@sma.org.sg.



  
 
Dopamine-secreting phaeochromocytomas and paragangliomas: clinical features and management
Adjust font size :   fontsmall   fontbig
 

Foo SH, Chan SP, Ananda V, Rajasingam V
Correspondence: Dr Foo Siew-Hui, jsiewhui@yahoo.com

ABSTRACT
Most functional phaeochromocytomas/paragangliomas produce noradrenaline and/or adrenaline. Those that produce dopamine are rare. We describe the distinguishing clinical features of dopamine-secreting phaeochromocytomas and paragangliomas from those that secrete noradrenaline/adrenaline and the impact on their management. We present a case of a dopamine-secreting paraganglioma from our institution and review 14 case reports of dopamine-secreting phaeochromocytomas/ paragangliomas published between 1984 and 2008. As observed in the literature, 80% of the tumours were extra-adrenal. Most patients presented with non-specific symptoms or mass effect without the classical presentation of catecholamine excess. The majority were diagnosed with urinary or plasma dopamine. Five patients had malignant tumours and 12 patients underwent surgical resection of the primary tumours. Unlike noradrenaline/adrenaline-secreting/phaeochromocytomas/paragangliomas, dopamine-secreting tumours lack a classical presentation, are extra-adrenal and have a higher malignant potential. A routine inclusion of urinary or plasma dopamine as part of catecholamine screening in all suspected phaeochromocytomas and paragangliomas is recommended.

Keywords: dopamine-secreting tumours, functional paraganglioma, phaeochromocytoma, plasma dopamine, urinary dopamine
Singapore Med J 2010; 51(5): e89-e93

[Full Text PDF]